Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin Perioperative Prophylaxis in Early Stage Melanoma
NCT04875728Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2020
- Primary completion
- Feb 2027
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised trial of cefazolin in cutaneous melanoma (CM) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Change in microbiome alpha diversity at 2 weeks. Started Sep 2020; status: active, not recruiting.
02
Drugs
cefazolin
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04875728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875728.